O	0	5	Final
O	6	13	results
O	14	18	from
O	19	22	the
O	23	34	prospective
O	35	40	phase
O	41	44	III
O	45	48	WSG
O	48	49	-
O	49	52	ARA
O	53	58	trial
O	58	59	:
O	60	66	impact
O	67	69	of
B-intervention	70	78	adjuvant
I-intervention	79	90	darbepoetin
I-intervention	91	95	alfa
O	96	98	on
O	99	104	event
O	104	105	-
O	105	109	free
O	110	118	survival
O	119	121	in
O	122	127	early
O	128	134	breast
O	135	141	cancer
O	141	142	.

O	143	146	WSG
O	146	147	-
O	147	150	ARA
O	151	155	plus
O	156	161	trial
O	162	171	evaluated
O	172	175	the
O	176	182	effect
O	183	185	of
O	186	194	adjuvant
O	195	206	darbepoetin
O	207	211	alfa
O	212	213	(
O	213	215	DA
O	215	216	)
O	217	219	on
O	220	227	outcome
O	228	230	in
B-eligibility	231	235	node
I-eligibility	236	244	positive
I-eligibility	245	252	primary
I-eligibility	253	259	breast
I-eligibility	260	266	cancer
I-eligibility	267	268	(
I-eligibility	268	270	BC
I-eligibility	270	271	)
O	271	272	.

B-total-participants	273	276	One
I-total-participants	277	285	thousand
I-total-participants	286	289	two
I-total-participants	290	297	hundred
I-total-participants	298	304	thirty
I-total-participants	304	305	-
I-total-participants	305	309	four
O	310	318	patients
O	319	323	were
O	324	334	randomized
O	335	337	to
O	338	350	chemotherapy
O	351	357	either
O	358	362	with
O	363	365	DA
O	366	367	(
O	367	369	DA
O	369	370	+
O	370	371	;
O	372	373	n
O	374	375	=
B-intervention-participants	376	379	615
O	379	380	)
O	381	383	or
B-control	384	391	without
I-control	392	394	DA
O	395	396	(
O	396	398	DA
O	398	399	-
O	399	400	;
O	401	402	n
O	403	404	=
B-control-participants	405	408	619
O	408	409	)
O	409	410	.

O	411	413	DA
O	414	415	(
O	415	418	500
O	419	420	µ
O	420	421	g
O	422	425	q3w
O	425	426	)
O	427	430	was
O	431	438	started
O	439	441	at
O	442	452	hemoglobin
O	453	454	(
O	454	456	Hb
O	456	457	)
O	458	464	levels
O	465	466	<
O	466	468	13
O	468	469	.
O	469	470	0
O	471	472	g
O	472	473	/
O	473	475	dl
O	476	477	(
O	477	478	<
O	478	480	12
O	481	482	g
O	482	483	/
O	483	485	dl
O	486	491	after
O	492	494	DA
O	495	500	label
O	501	510	amendment
O	510	511	)
O	512	515	and
O	516	523	stopped
O	524	526	at
O	527	529	Hb
O	530	536	levels
O	537	538	≥
O	538	540	14
O	540	541	.
O	541	542	0
O	543	544	g
O	544	545	/
O	545	547	dl
O	548	549	(
O	549	551	12
O	552	553	g
O	553	554	/
O	554	556	dl
O	557	562	after
O	563	568	label
O	569	578	amendment
O	578	579	)
O	579	580	.

O	581	588	Primary
O	589	597	efficacy
O	598	601	end
O	602	607	point
O	608	611	was
B-outcome-Measure	612	617	event
I-outcome-Measure	617	618	-
I-outcome-Measure	618	622	free
I-outcome-Measure	623	631	survival
I-outcome-Measure	632	633	(
I-outcome-Measure	633	636	EFS
I-outcome-Measure	636	637	)
O	637	638	;
O	639	648	secondary
O	649	652	end
O	653	659	points
O	660	664	were
B-outcome-Measure	665	673	toxicity
O	673	674	,
B-outcome-Measure	675	682	quality
I-outcome-Measure	683	685	of
I-outcome-Measure	686	690	life
I-outcome-Measure	691	692	(
I-outcome-Measure	692	695	QoL
I-outcome-Measure	695	696	)
O	697	700	and
B-outcome-Measure	701	708	overall
I-outcome-Measure	709	717	survival
I-outcome-Measure	718	719	(
I-outcome-Measure	719	721	OS
I-outcome-Measure	721	722	)
O	722	723	.

B-outcome	724	730	Venous
I-outcome	731	741	thrombosis
O	742	743	(
O	743	745	DA
O	745	746	+
O	746	747	:
B-iv-bin-percent	748	749	3
I-iv-bin-percent	749	750	.
I-iv-bin-percent	750	751	0
I-iv-bin-percent	751	752	%
O	752	753	,
O	754	756	DA
O	756	757	-
O	757	758	:
B-cv-bin-percent	759	760	1
I-cv-bin-percent	760	761	.
I-cv-bin-percent	761	762	0
I-cv-bin-percent	762	763	%
O	763	764	;
O	765	766	P
O	767	768	=
O	769	770	0
O	770	771	.
O	771	774	013
O	774	775	)
O	776	779	was
O	780	793	significantly
O	794	800	higher
O	801	804	for
O	805	807	DA
O	807	808	+
O	808	809	,
O	810	813	but
O	814	817	not
B-outcome	818	827	pulmonary
I-outcome	828	836	embolism
O	837	838	(
B-iv-bin-percent	838	839	0
I-iv-bin-percent	839	840	.
I-iv-bin-percent	840	841	3
I-iv-bin-percent	841	842	%
O	843	845	in
O	846	850	both
O	851	855	arms
O	855	856	)
O	856	857	.

B-outcome	858	864	Median
I-outcome	865	867	Hb
I-outcome	868	874	levels
O	875	879	were
O	880	886	stable
O	887	889	in
O	890	892	DA
O	892	893	+
O	894	895	(
B-iv-cont-median	895	897	12
I-iv-cont-median	897	898	.
I-iv-cont-median	898	899	6
I-iv-cont-median	900	901	g
I-iv-cont-median	901	902	/
I-iv-cont-median	902	904	dl
O	904	905	)
O	906	909	and
O	910	919	decreased
O	920	922	in
O	923	925	DA
O	925	926	-
O	927	928	(
B-cv-cont-median	928	930	11
I-cv-cont-median	930	931	.
I-cv-cont-median	931	932	7
I-cv-cont-median	933	934	g
I-cv-cont-median	934	935	/
I-cv-cont-median	935	937	dl
O	937	938	)
O	938	939	.

B-outcome	940	942	Hb
I-outcome	943	949	levels
I-outcome	950	951	>
I-outcome	951	953	15
I-outcome	954	955	g
I-outcome	955	956	/
I-outcome	956	958	dl
O	959	963	were
O	964	972	reported
O	973	975	in
O	976	977	0
O	977	978	.
O	978	979	8
O	979	980	%
O	981	983	of
O	984	990	cycles
O	990	991	.

B-outcome	992	995	QoL
O	996	1006	parameters
O	1007	1010	did
O	1011	1014	not
O	1015	1028	significantly
O	1029	1035	differ
O	1036	1043	between
O	1044	1048	arms
O	1048	1049	.

B-outcome	1050	1052	At
I-outcome	1053	1055	39
I-outcome	1056	1062	months
O	1062	1063	,
O	1064	1066	DA
O	1067	1070	had
O	1071	1073	no
O	1074	1085	significant
O	1086	1092	impact
O	1093	1095	on
B-outcome	1096	1099	EFS
O	1100	1101	(
O	1101	1103	DA
O	1103	1104	+
O	1104	1105	:
B-iv-bin-percent	1106	1108	89
I-iv-bin-percent	1108	1109	.
I-iv-bin-percent	1109	1110	3
I-iv-bin-percent	1110	1111	%
O	1111	1112	,
O	1113	1115	DA
O	1115	1116	-
O	1116	1117	:
B-cv-bin-percent	1118	1120	87
I-cv-bin-percent	1120	1121	.
I-cv-bin-percent	1121	1122	5
I-cv-bin-percent	1122	1123	%
O	1123	1124	;
O	1125	1129	Plog
O	1129	1130	-
O	1130	1134	rank
O	1135	1136	=
O	1137	1138	0
O	1138	1139	.
O	1139	1141	55
O	1141	1142	)
O	1143	1145	or
B-outcome	1146	1148	OS
O	1149	1150	(
O	1150	1152	DA
O	1152	1153	+
O	1153	1154	:
B-iv-bin-percent	1155	1157	95
I-iv-bin-percent	1157	1158	.
I-iv-bin-percent	1158	1159	5
I-iv-bin-percent	1159	1160	%
O	1160	1161	,
O	1162	1164	DA
O	1164	1165	-
O	1165	1166	:
B-cv-bin-percent	1167	1169	95
I-cv-bin-percent	1169	1170	.
I-cv-bin-percent	1170	1171	4
I-cv-bin-percent	1171	1172	%
O	1172	1173	;
O	1174	1178	Plog
O	1178	1179	-
O	1179	1183	rank
O	1184	1185	=
O	1186	1187	0
O	1187	1188	.
O	1188	1190	77
O	1190	1191	)
O	1191	1192	.

O	1193	1195	DA
O	1196	1205	treatment
O	1206	1209	did
O	1210	1213	not
O	1214	1220	impact
O	1221	1224	EFS
O	1225	1227	or
O	1228	1230	OS
O	1231	1233	in
O	1234	1241	routine
O	1242	1250	adjuvant
O	1251	1253	BC
O	1254	1263	treatment
O	1263	1264	.
